Literature DB >> 2352323

The site of an immune-selected point mutation in the transmembrane protein of human immunodeficiency virus type 1 does not constitute the neutralization epitope.

C Wilson1, M S Reitz, K Aldrich, P J Klasse, J Blomberg, R C Gallo, M Robert-Guroff.   

Abstract

We previously reported the in vitro generation of a neutralization-resistant variant of the molecularly cloned isolate of human immunodeficiency virus type 1 (HIV-1), HXB2D. The molecular basis for the resistance was shown to be a point mutation in the env gene, causing the substitution of threonine for alanine at position 582 of gp41. Here, we show the variant to be resistant to syncytium inhibition as well as to neutralization by the immune-selecting serum. Moreover, 30% of HIV-positive human sera able to neutralize the parental virus have significantly decreased ability to neutralize the variant. As the A-to-T substitution thus has general relevance to the interaction of HIV-1 with the host immune system, we investigated further the biologic and immunologic bases for the altered properties. Synthetic peptides corresponding to the 582 region failed to compete in infectivity, neutralization, or syncytium inhibition assays and did not elicit neutralizing antibodies. Furthermore, human antibodies, affinity purified on synthetic peptide resins, bound to gp41 and peptides from the 582 region but did not possess neutralizing antibody activity. Some viral constructs in which the AVERY sequence in the 582 region was altered by site-directed mutagenesis were not infectious, indicating that the primary structure in this region is crucial for viral infectivity. Constructs predicted to possess a local secondary structure similar to that of the variant nevertheless behaved like the parental virus and remained neutralization sensitive. These results suggest that the requirements for neutralization resistance in this region are very precise. Our results with synthetic peptides show that the 582 region does not by itself constitute a neutralization epitope. Moreover, the degree of flexibility in amino acid substitution which allows maintenance of neutralization sensitivity suggests that position 582 does not form part of a noncontiguous neutralization epitope. The basis for neutralization resistance of the immune-selected variant is more likely a conformational change altering a neutralization epitope at a distant site.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2352323      PMCID: PMC249544     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  36 in total

1.  Oligomeric structure of gp41, the transmembrane protein of human immunodeficiency virus type 1.

Authors:  A Pinter; W J Honnen; S A Tilley; C Bona; H Zaghouani; M K Gorny; S Zolla-Pazner
Journal:  J Virol       Date:  1989-06       Impact factor: 5.103

2.  Antigenic drift of equine infectious anemia virus in chronically infected horses.

Authors:  Y Kono; K Kobayashi; Y Fukunaga
Journal:  Arch Gesamte Virusforsch       Date:  1973

3.  Antigenic variation in visna virus.

Authors:  J V Scott; L Stowring; A T Haase; O Narayan; R Vigne
Journal:  Cell       Date:  1979-10       Impact factor: 41.582

4.  An engineered poliovirus chimaera elicits broadly reactive HIV-1 neutralizing antibodies.

Authors:  D J Evans; J McKeating; J M Meredith; K L Burke; K Katrak; A John; M Ferguson; P D Minor; R A Weiss; J W Almond
Journal:  Nature       Date:  1989-06-01       Impact factor: 49.962

5.  B- and T-lymphocyte responses to an immunodominant epitope of human immunodeficiency virus.

Authors:  R D Schrier; J W Gnann; A J Langlois; K Shriver; J A Nelson; M B Oldstone
Journal:  J Virol       Date:  1988-08       Impact factor: 5.103

6.  DNA sequencing with chain-terminating inhibitors.

Authors:  F Sanger; S Nicklen; A R Coulson
Journal:  Proc Natl Acad Sci U S A       Date:  1977-12       Impact factor: 11.205

7.  Human immunodeficiency virus type 1 neutralization epitope with conserved architecture elicits early type-specific antibodies in experimentally infected chimpanzees.

Authors:  J Goudsmit; C Debouck; R H Meloen; L Smit; M Bakker; D M Asher; A V Wolff; C J Gibbs; D C Gajdusek
Journal:  Proc Natl Acad Sci U S A       Date:  1988-06       Impact factor: 11.205

8.  Characterization of a human immunodeficiency virus neutralizing monoclonal antibody and mapping of the neutralizing epitope.

Authors:  S Matsushita; M Robert-Guroff; J Rusche; A Koito; T Hattori; H Hoshino; K Javaherian; K Takatsuki; S Putney
Journal:  J Virol       Date:  1988-06       Impact factor: 5.103

9.  Antibodies that inhibit fusion of human immunodeficiency virus-infected cells bind a 24-amino acid sequence of the viral envelope, gp120.

Authors:  J R Rusche; K Javaherian; C McDanal; J Petro; D L Lynn; R Grimaila; A Langlois; R C Gallo; L O Arthur; P J Fischinger
Journal:  Proc Natl Acad Sci U S A       Date:  1988-05       Impact factor: 11.205

10.  Presence of antibodies to a putatively immunosuppressive part of human immunodeficiency virus (HIV) envelope glycoprotein gp41 is strongly associated with health among HIV-positive subjects.

Authors:  P J Klasse; R Pipkorn; J Blomberg
Journal:  Proc Natl Acad Sci U S A       Date:  1988-07       Impact factor: 11.205

View more
  39 in total

Review 1.  Cellular and humoral antigenic epitopes in HIV and SIV.

Authors:  D F Nixon; K Broliden; G Ogg; P A Broliden
Journal:  Immunology       Date:  1992-08       Impact factor: 7.397

2.  Selection of genetic variants of simian immunodeficiency virus in persistently infected rhesus monkeys.

Authors:  D P Burns; R C Desrosiers
Journal:  J Virol       Date:  1991-04       Impact factor: 5.103

3.  Alternative coreceptor requirements for efficient CCR5- and CXCR4-mediated HIV-1 entry into macrophages.

Authors:  Kieran Cashin; Michael Roche; Jasminka Sterjovski; Anne Ellett; Lachlan R Gray; Anthony L Cunningham; Paul A Ramsland; Melissa J Churchill; Paul R Gorry
Journal:  J Virol       Date:  2011-08-10       Impact factor: 5.103

4.  Potent antibody-mediated neutralization and evolution of antigenic escape variants of simian immunodeficiency virus strain SIVmac239 in vivo.

Authors:  Shuji Sato; Eloisa Yuste; William A Lauer; Eun Hyuk Chang; Jennifer S Morgan; Jacqueline G Bixby; Jeffrey D Lifson; Ronald C Desrosiers; Welkin E Johnson
Journal:  J Virol       Date:  2008-07-30       Impact factor: 5.103

5.  Resistance of a human serum-selected human immunodeficiency virus type 1 escape mutant to neutralization by CD4 binding site monoclonal antibodies is conferred by a single amino acid change in gp120.

Authors:  J A McKeating; J Bennett; S Zolla-Pazner; M Schutten; S Ashelford; A L Brown; P Balfe
Journal:  J Virol       Date:  1993-09       Impact factor: 5.103

6.  Immune escape by human immunodeficiency virus type 1 from neutralizing antibodies: evidence for multiple pathways.

Authors:  B A Watkins; M S Reitz; C A Wilson; K Aldrich; A E Davis; M Robert-Guroff
Journal:  J Virol       Date:  1993-12       Impact factor: 5.103

7.  Mutations in both gp120 and gp41 are responsible for the broad neutralization resistance of variant human immunodeficiency virus type 1 MN to antibodies directed at V3 and non-V3 epitopes.

Authors:  E J Park; L K Vujcic; R Anand; T S Theodore; G V Quinnan
Journal:  J Virol       Date:  1998-09       Impact factor: 5.103

Review 8.  How can HIV-type-1-Env immunogenicity be improved to facilitate antibody-based vaccine development?

Authors:  Per Johan Klasse; Rogier W Sanders; Andrea Cerutti; John P Moore
Journal:  AIDS Res Hum Retroviruses       Date:  2011-05-20       Impact factor: 2.205

9.  Genetic signatures in the envelope glycoproteins of HIV-1 that associate with broadly neutralizing antibodies.

Authors:  S Gnanakaran; Marcus G Daniels; Tanmoy Bhattacharya; Alan S Lapedes; Anurag Sethi; Ming Li; Haili Tang; Kelli Greene; Hongmei Gao; Barton F Haynes; Myron S Cohen; George M Shaw; Michael S Seaman; Amit Kumar; Feng Gao; David C Montefiori; Bette Korber
Journal:  PLoS Comput Biol       Date:  2010-10-07       Impact factor: 4.475

Review 10.  Pathogenesis of human immunodeficiency virus infection.

Authors:  J A Levy
Journal:  Microbiol Rev       Date:  1993-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.